Found: 1
Select item for more details and to access through your institution.
PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study.
- Published in:
- Prostate, 2020, v. 80, n. 1, p. 99, doi. 10.1002/pros.23922
- By:
- Publication type:
- Article